Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. The presentation is scheduled for January 9, 2023, at 7:30 am PT (10:30 am ET), led by President and CEO Ian Mortimer. Investors can access a live webcast of the presentation on the company’s website, with a replay available afterward. Xenon focuses on developing innovative treatments for neurological disorders, particularly epilepsy, aiming to address significant unmet medical needs.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was +1.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 9-12, 2023.
Company Presentation Details:
| Date: | Monday, January 9, 2023 |
| Time: | 7:30 am Pacific Time (10:30 am Eastern Time) |
| Presenters: | Ian Mortimer, President and CEO |
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.